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INTRODUCTION
Uterine carcinosarcoma/malignant mixed Müllerian tumor 
(UC/MMMT) is an uncommon and aggressive gynecological 
malignancy with poor prognosis. Tumors arise from mono-
clonal carcinoma cells derived from embryonal mesoderm, 
which exhibit sarcomatous metaplasia. UC/MMMT usually 
occurs in postmenopausal women and accounts for 2%–5% 
of all uterine malignancies [1,2]. The five-year survival rates are 
particularly poor (21%–39%). Several case reports and case 
series describe UC/MMMT occurring after tamoxifen therapy 
for breast cancer [3-9]. Retrospective studies suggest that the 
increased incidence of these high-risk malignancies is greater 
than the observed increase in incidence of endometrial 
tumors generally following tamoxifen therapy [10-13], though 
the number of subjects with UC/MMMT in any of these stud-
ies is small. The increase in uterine cancers generally following 
tamoxifen therapy is thought to be driven by the estrogen 
receptor alpha (ERa) through a positive trophic effect on the 
uterine corpus. Although tamoxifen binds ERβ with equal 
affinity, there is no observed activation of this receptor [14,15]. 
Whether ER activation exerts any positive effect on UC/
MMMTs remains equivocal. Other studies suggest that tamoxi-
fen may upregulate expression of the HER2/neu oncogene in 
UC/MMMT cells [16,17], although any potential effect on the 
behavior of these malignancies is far from clear. As tamoxifen 
metabolites can covalently bind DNA, principally forming (E)- 
and (Z)-a-(deoxyguanosin-N2-yl)-4-hydroxytamoxifen adducts 
[18], the possibility that tamoxifen therapy is inherently carci-
nogenic has also been considered. However, tamoxifen-DNA 
adduct formation in uterine tissues following oral administra-
tion occurs at levels too low to be consistent with this being 
the mechanism driving such endometrial cancers [19].
We identified two unrelated women who developed UC/
MMMT as a second primary malignancy following BRCA1-
associated breast cancer. Neither of these women received 
hormone therapy, as their tumors were histologically 
determined to be unresponsive to hormone therapy (i.e., ER-/
progesterone receptor [PR]-). Patient 1 had BRCA1 c.5503C>T 
(p.Arg1835*), developed breast cancer at 36 years, which 
was managed with lumpectomy and local radiotherapy, and 
subsequently developed UC/MMMT at 48 years. Patient 2 had 
BRCA1 c.2560_2561dupGC (p.Gln855fs), developed breast 
cancer at 34 years, again treated with lumpectomy and local 
radiotherapy, and was found to have UC/MMMT at 56 years. 
Although BRCA1 mutation carriers are at increased risk of 
developing endometrial cancers compared to the general 
population, most of this risk is attributable to tamoxifen use 
[20]. It has also been suggested that BRCA1 mutations may 
predispose carriers to uterine papillary serous carcinoma 
specifically [21,22]. However, UC/MMMT is not recognized as 
part of the BRCA1 phenotype. Prompted by this unexpected 
finding, we conducted a retrospective population-based 
study to establish whether an association exists between 
breast cancer and UC/MMMT generally and whether a breast 
tumor being ER-/PR- has any bearing on this.
METHODS
We reviewed data from all 387 patients in the Northern 
and Yorkshire Cancer Registry who were diagnosed with UC/
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MMMT between January 1998 and December 2007. We also 
analyzed data for all 85,930 women who could have potential-
ly developed UC/MMMT following breast cancer during this 
period, i.e., any woman alive for any part of the study period 
who had been diagnosed with breast cancer at any time prior 
to the study end date. Data included age at cancer diagnoses 
and whether hormone therapy had been given at any time for 
this, as a proxy for ER/PR status of the breast cancer. All study 
information was released to us in fully anonymized form. As 
cancer registration is a statutory requirement in the UK, we 
expect our dataset to be fully representative of the registry 
population, although we cannot exclude the possibility of mi-
nor omissions in the recording of therapies that were started 
after the registered treatment period. 
RESULTS AND DISCUSSION
Three hundred eighty-seven patients were diagnosed with 
UC/MMMT between January 1998 and December 2007, 
accounting for 5.7% of all recorded uterine malignancies. The 
mean age at diagnosis was 71 years (range, 28 to 101 years). 
85,930 women were alive for at least part of the study period 
having been diagnosed with breast cancer. In 87 of UC/MMMT 
cases (22.5%), UC/MMMT represented a second primary 
malignancy following breast cancer, with an interval of 10–20 
years. In a further six UC/MMMT patients (1.6%), UC/MMMT 
preceded a diagnosis of breast cancer. This co-occurrence of 
breast cancer together with UC/MMMT in 24% of UC/MMMT 
patients is significantly higher (p<0.001) than the breast cancer 
rate (3.0%) seen, at the midpoint of the study period, in women 
>20 years of age without UC/MMMT. Kaplan-Meier estimates 
were used with a Cox proportional hazards regression to test 
the effect of hormone therapy on time to UC/MMMT following 
breast cancer, against the hypothesis that there would be no 
difference between the groups. Hormone therapy, as a proxy 
for hormone receptor status, has no significant effect on the 
development of UC/MMMT following breast cancer (p=0.55) 
(Fig. 1). However, the number of cases of UC/MMMT occur-
ring in women following an independent diagnosis of breast 
cancer (87 out of 85,930) is higher than expected (p<0.001).
This study comprises the largest cohort of UC/MMMT pa-
tients to date and suggests that receipt of hormone therapy 
for breast cancer has negligible effect on the incidence of 
these tumors. However, the observation that UC/MMMT is 
overrepresented in our breast cancer population suggests 
that there may be an as yet unknown, possibly genetic, com-
ponent to the development of such malignancies. Another 
potential explanation is that systemic treatment for a primary 
cancer, i.e., chemotherapy, may increase the likelihood of a 
second malignancy among treated individuals; however, our 
patients were managed with surgery and local radiotherapy 
only. Having identified unrelated women diagnosed with UC/
MMMT following ER-/PR-, BRCA1-associated breast cancers, it 
may be that these aggressive gynecological tumors are a rare 
manifestation of this high risk genetic cancer predisposition 
syndrome, which may be avoided by prophylactic hysterec-
tomy. While the risk-reducing role of prophylactic bilateral 
salpingo-oophorectomy in promoting long-term survival 
among BRCA1/2 carriers is already established [23], a similar 
approach may not be clinically practicable for malignancies 
as rare as UC/MMMT. Further genetic studies of the UC/
MMMT population are required to properly establish whether 
BRCA1/2―or other genes―make a substantial contribution to 
this clinical phenotype. If so, newer, targeted therapies, such 
as the PARP inhibitors [24], may be considered as potential 
candidates to reduce mortality associated with UC/MMMT.
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Fig. 1. Kaplan-Meier estimates of time to uterine carcinosarcoma/
malignant mixed Müllerian tumor (UC/MMMT) following breast cancer 
diagnosis, with and without hormone therapy for the breast cancer. 
There is no difference between the groups.
0
1.0
25
Time from diagnosis of breast cancer to UC/MMMT (yr)
Hormone therapy
No hormone therapy
5 10 2015
S
u
rv
iv
a
l
Uterine carcinosarcoma and breast cancer
J Gynecol Oncol Vol. 26, No. 4:249-251 www.ejgo.org 251
REFERENCES
 1. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed 
Müllerian tumor) of the uterus: advances in elucidation of biologic 
and clinical characteristics. J Natl Compr Canc Netw 2009;7:550-6.
 2. Ho SP, Ho TH. Malignant mixed Mullerian tumours of the uterus: a 
ten-year experience. Singapore Med J 2002;43:452-6. 
 3. Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt 
W. Carcinosarcoma, endometrial intraepithelial carcinoma and 
endometriosis after tamoxifen therapy in breast cancer. Eur J 
Obstet Gynecol Reprod Biol 1999;82:85-7. 
 4. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N. 
Long-term tamoxifen treatment: a possible aetiological factor in 
the development of uterine carcinosarcoma: two case-reports and 
review of the literature. Anticancer Res 2000;20:2015-20. 
 5. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton 
S, Beattie J, et al. Uterine carcinosarcomas in patients receiving 
tamoxifen: a report of 19 cases. Int J Gynecol Cancer 2000;10:280-4. 
 6. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, 
et al. Tamoxifen-related uterine carcinosarcomas occur under/
after prolonged treatment: report of five cases and review of the 
literature. Int J Gynecol Cancer 2002;12:496-500. 
 7. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C. Malignant mixed 
mesodermal tumor after tamoxifen therapy for breast cancer. 
Gynecol Oncol 2004;95:264-6. 
 8. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. 
Development of uterine sarcoma after tamoxifen treatment for 
breast cancer: report of four cases. Int J Gynecol Cancer 2005;15: 
1239-42. 
 9. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jorcano S, Mellado 
B, et al. Uterine sarcomas in breast cancer patients treated with 
tamoxifen. Int J Gynecol Cancer 2006;16:861-5. 
 10. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of 
malignant mixed mullerian tumors after tamoxifen therapy for 
breast cancer. J Natl Cancer Inst 2004;96:70-4. 
 11. Rieck GC, Freites ON, Williams S. Is tamoxifen associated with high-
risk endometrial carcinomas? A retrospective case series of 196 
women with endometrial cancer. J Obstet Gynaecol 2005;25:39-41. 
 12. Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer 
Study Group. Tamoxifen treatment for breast cancer and risk of 
endometrial cancer: a case-control study. J Natl Cancer Inst 2005; 
97:375-84. 
 13. Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie 
E, et al. Outcomes in patients with primary breast cancer and 
a subsequent diagnosis of endometrial cancer: comparison of 
cohorts treated with and without tamoxifen. Cancer 2007;110:31-7. 
 14. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, et al. 
Agonistic effect of tamoxifen is dependent on cell type, ERE-
promoter context, and estrogen receptor subtype: functional 
difference between estrogen receptors alpha and beta. Biochem 
Biophys Res Commun 1997;236:140-5. 
 15. Zafrakas M, Kostopoulou E, Dragoumis K, Mikos T, Papadimas J, 
Bontis J. Expression of estrogen receptors alpha and beta in two 
uterine mesenchymal tumors after prolonged tamoxifen therapy: 
report of two cases. Eur J Gynaecol Oncol 2004;25:530-3. 
 16. Raspollini MR, Mecacci F, Paglierani M, Marchionni M, Taddei GL. 
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen 
therapy. Pathol Res Pract 2005;201:141-4. 
 17. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, 
Verbist L, Moerman P, et al. ERBB-2 gene overexpression and 
amplification in uterine sarcomas. Gynecol Oncol 2004;95:583-7. 
 18. Marques MM, Beland FA. Identification of tamoxifen-DNA adducts 
formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 
1997;18:1949-54. 
 19. Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, 
et al. Tamoxifen DNA damage detected in human endometrium 
using accelerator mass spectrometry. Cancer Res 2003;63:8461-5. 
 20. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The 
incidence of endometrial cancer in women with BRCA1 and BRCA2 
mutations: an international prospective cohort study. Gynecol 
Oncol 2013;130:127-31. 
 21. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, et 
al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous 
carcinoma. Cancer 2013;119:332-8. 
 22. Hecht JL, Konstantinopoulos PA, Awtrey CS, Soslow RA. Immuno-
histochemical loss of BRCA1 protein in uterine serous carcinoma. 
Int J Gynecol Pathol 2014;33:282-7. 
 23. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, 
et al. Contralateral mastectomy improves survival in women 
with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 
2013;140:135-42. 
 24. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. 
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor 
AG014699 in human cancers with mutated or methylated BRCA1 
or BRCA2. J Natl Cancer Inst 2011;103:334-46. 
█              █              █
